Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 353

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 353
---
 CERo Supporting Stockholder agreed that, at any meeting of the holders of CERo capital stock, each such CERo Supporting Stockholder will appear at the meeting, in person or by proxy, and cause its Subject CERo Shares to be counted as present thereat for purposes of calculating a quorum and voted (i) to approve and adopt the Business Combination Agreement, the transactions contemplated thereby (including the Business Combination), and any other matters necessary or reasonably requested by CERo for consummation of the Business Combination, and (ii) against any proposal that conflicts or materially impedes or interferes with, or would adversely affect or delay, the consummation of the transactions contemplated by the Business Combination Agreement (including the Business Combination). Note 7 — Stockholders’ Deficit Common Stock Class A common stock— The Company is authorized to issue 60,000,000shares of Class A common stock with a par value of $ 0.0001per share. As of December 31, 2023 and 2022, there were 5,481,250and 885,000shares of Class A common stock issued and outstanding (excluding 764,957and 1,288,298shares subject to possible redemption), respectively. Class B common stock— The Company is authorized to issue 10,000,000shares of Class B common stock with a par value of $ 0.0001per share. Holders of Class B common stock are entitled to onevote for each share. On July 3, 2023, the Sponsor delivered notice of conversion of an aggregate of 4,596,250shares of Class B common stock into an equal number of shares of Class A common stock. As of December 31, 2023 and 2022, there were 0and 4,596,250shares of Class B common stock issued and outstanding. Prior to the consummation of an initial business combination, only holders of shares of Class B common stock will have the right to vote on the election of directors. Holders of shares of Class A common stock and shares of Class B common stock will vote together as a single class on all other matters submitted to a vote of stockholders. F-43 PHOENIX BIOTECH ACQUISITION CORP. NOTES TO FINANCIAL STATEMENTS DECEMBER 31, 2023

Preferred stock
— The Company is authorized to issue shares of preferred stock with such designations, voting and